CCM
VERA icon

CAAS Capital Management’s Vera Therapeutics VERA Stock Holding History

CAAS Capital Management’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-20,000
Closed -$265K – 1121
2021
Q2 		$265K Buy
+20,000
New +$311K ﹤0.01% 834

Other funds holding VERA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KXA
KPCB XVI Associates Menlo Park, California $225M AUM 26.26% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CAAS Capital Management's VERA Position: Q3 2021 in Review

CAAS Capital Management sold out of Vera Therapeutics (VERA) in Q3 2021, closing a stake of 20,000 shares — an estimated $265K sold.

CAAS Capital Management first reported a position in VERA in Q2 2021 and held it in 1 quarter. The position peaked at $265K in Q2 2021. 31 funds tracked by Wall St. Rank hold VERA as of Q3 2021.

  • CAAS Capital Management reported no remaining Vera Therapeutics position as of Q3 2021 after selling out during the quarter.
  • CAAS Capital Management sold 20,000 Vera Therapeutics shares in Q3 2021, an estimated $265K.
  • CAAS Capital Management first reported a position in Vera Therapeutics in Q2 2021 and held it in 1 quarter.
  • CAAS Capital Management's Vera Therapeutics position peaked at $265K in Q2 2021.
  • 31 funds tracked by Wall St. Rank held Vera Therapeutics as of Q3 2021.

Based on CAAS Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.